

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
  - 5 (a) a first nucleotide sequence encoding a polypeptide of at least 60 amino acids selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36; or
  - (b) a second nucleotide sequence comprising a complement of the first nucleotide sequence.
- 10 2. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35.
3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are DNA.
- 15 4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are RNA.
5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to at least one suitable regulatory sequence.
6. A host cell comprising the chimeric gene of Claim 5.
- 20 7. A host cell comprising the isolated polynucleotide of Claim 1.
8. The host cell of Claim 7 wherein the host cell is selected from the group consisting of yeast, bacteria, and plant.
9. A virus comprising the isolated polynucleotide of Claim 1.
10. A polypeptide of at least 60 amino acids selected from the group consisting of
- 25 SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
11. A method of selecting an isolated polynucleotide that affects the level of expression of a disease resistance factor polypeptide in a plant cell, the method comprising the steps of:
  - (a) constructing the isolated polynucleotide comprising a nucleotide sequence of
  - 30 at least one of 30 contiguous nucleotides derived from the isolated polynucleotide of Claim 1;
  - (b) introducing the isolated polynucleotide into the plant cell;
  - (c) measuring the level of the polypeptide in the plant cell containing the polynucleotide; and
  - 35 (d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the isolated polynucleotide.

12. The method of Claim 11 wherein the isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35.

5 13. A method of selecting an isolated polynucleotide that affects the level of expression of a disease resistance factor polypeptide in a plant cell, the method comprising the steps of:

- (a) constructing the isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into the plant cell;
- (c) measuring the level of the polypeptide in the plant cell containing the
- 10 polynucleotide; and
- (d) comparing the level of the polypeptide in the plant cell containing the isolated polynucleotide with the level of the polypeptide in a plant cell that does not contain the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding a disease resistance

15 factor polypeptide comprising the steps of:

- (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 and a complement of such nucleotide sequences; and
- 20 (b) amplifying a nucleic acid sequence using the oligonucleotide primer.

15. A method of obtaining a nucleic acid fragment encoding a disease resistance factor polypeptide comprising the steps of:

- (a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence
- 25 selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 and a complement of such nucleotide sequences;
- (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;
- (c) isolating the identified DNA clone; and
- (d) sequencing a cDNA or genomic fragment that comprises the isolated DNA
- 30 clone.

16. A composition comprising the isolated polynucleotide of Claim 1.

17. A composition comprising the isolated polypeptide of Claim 10.

18. The isolated polynucleotide of Claim 1 comprising a nucleotide sequence having at least one of 30 contiguous nucleotides.

35 19. A method for positive selection of a transformed cell comprising:

- (a) transforming a host cell with the chimeric gene of Claim 5; and

(b) growing the transformed host cell under conditions which allow expression of a polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

20. The method of Claim 19 wherein the host cell is a plant.

5 21. The method of Claim 20 wherein the plant cell is a monocot.

22. The method of Claim 20 wherein the plant cell is a dicot.

23. A method of altering the level of expression of a disease resistance factor in a host cell comprising:

(a) transforming the host cell with the chimeric gene of Claim 5; and

10 (b) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene

wherein expression of the chimeric gene results in production of altered levels of the disease resistance factor in the transformed host cell.

24. A method for evaluating at least one compound for its ability to inhibit the activity of an LLS1 protein, the method comprising the steps of:

(a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding the LLS1 protein, operably linked to at least one suitable regulatory sequence;

20 (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of the LLS1 protein encoded by the operably linked nucleic acid fragment in the transformed host cell;

(c) optionally purifying the LLS1 protein expressed by the transformed host cell;

25 (d) treating the LLS1 protein polypeptide with a compound to be tested; and

(e) comparing the activity of the LLS1 protein that has been treated with the test compound to the activity of an untreated LLS1 protein, thereby selecting compounds with potential for inhibitory activity.